From developmentto commercialization.
BioAdaptives® has spent the past two years building the scientific, product, operational, and leadership foundation for its next phase. Today, the company is moving from platform development toward commercial execution.
- Human Clinical Data
268.8% increase in circulating stem/progenitor-type cells
- Commercial Platforms
Xcellara™ and MyndSystem™ commercially available today
- Supply Chain Complete
Commercial manufacturing and logistics in place
- Capital Structure Action
Largest convertible commercial investor debt retired
The transformation began with leadership.
James E. Keener became Chairman and Chief Executive Officer in May 2024, an operator and turnaround executive rather than a career laboratory scientist.
His early emergency-response work as a firefighter and EMT shaped an operating mindset centered on rapid assessment, prioritization, and decisive action.
Understand the situation.
Focus on what matters most.
Execute decisively.
Identified the strongest scientific foundation and concentrated the portfolio on it, discontinuing legacy product lines.
Human Renewal.
Keener recognized that the opportunity extended beyond a single formulation. The scientific foundation behind PrimiCell, later repositioned as Xcellara™, could support platforms addressing multiple dimensions of human wellness.
Added public-company, commercial, and human-performance experience.
Built the scientific, product, operational, and commercial foundation.
Before you decide what to change, you have to understand what you're looking at.
The foundation has been built.The next phase is commercialization.
The investor question changes with it: not what is being developed, but how effectively it can be commercialized.
What was built.
A platform model rather than a single product.
- Science
A cellular-mobilization base supported by human clinical data, with the dual-action technology explained in public disclosure.
- Platforms
Xcellara™ for cellular wellness and MyndSystem™ for cognitive performance and recovery.
- Products
XcellaraHeart™ and the completed day-and-night MyndSystem™ formulations.
- Infrastructure
Commercial manufacturing, logistics, and digital storefront operations.
Science-driven, and publicly documented.
The clearest evidence is the human clinical data underlying the Xcellara™ cellular-mobilization base, disclosed publicly by the company.
As disclosed on July 15, 2026, XcellaraHeart™ is a cardiovascular wellness formula built on Xcellara's human clinical data demonstrating a 268.8% increase in circulating stem/progenitor-type cells. The figure is stated here exactly as disclosed, without extension to any other product, population, or outcome.
Building the product is one phase. Building the business around it is the next.
What has changed most recently.
Recent disclosures show commercial readiness becoming commercial availability.
- Jun 25MyndSystem™ Platform Completed
TruShield certification of MyndRenew™ completed the platform, described as securing full WADA compliance for professional athletes.
Disclosure → - Jul 23Supply Chain Complete
Commercial manufacturing and logistics readiness completed ahead of upcoming product launches.
Disclosure → - Jul 29E-Commerce Expansion
Scaling of digital storefront operations and consumer marketing footprint for MyndSystem™.
Disclosure → - Aug 3Commercial Availability
Commercial ordering window opened for XcellaraHeart™ through products.xcellara.com.
Disclosure →
Addressing a legacy capital overhang.
On July 30, 2026, BioAdaptives® announced that it had retired the debt of its largest convertible commercial investor, describing the transaction as alleviating dilutive pressure ahead of product launches.
Read the disclosureWhat happens next is measurable.
These are areas through which the next phase can be observed over time. They are not predictions, forecasts, or commitments.
- Distribution
Are channels expanding?
- Market Development
Is awareness growing?
- Partnerships
Are commercial relationships developing?
- Commercial Adoption
Are the platforms gaining traction?
Eventually, strategy has to become execution.
Execution becomes the measure.
From here, progress can increasingly be evaluated through observable commercial execution.
Public disclosures and company information.
- OTC Markets
Public quote, disclosures, and company profile.
Open → - SEC EDGAR
Filings and public financial disclosures.
Open → - Latest News
The latest developments from BioAdaptives®.
Open →
Drew Parker
Investor Relations · BioAdaptives®, Inc.
Follow the next phase of BioAdaptives®.
Company news, public disclosures, and Investor Relations remain the direct sources for following how the next phase develops.